Looking to gain an edge as its broader obesity ambitions take shape, Pfizer has picked up the rights to a recently approved GLP-1 in China, unlocking an immediate commercial opportunity in type 2 diabetes, with the potential for a weight
read moreThe family of a Baltimore woman whose cells were extracted for medical research without her consent 75 years ago has settled a lawsuit with Novartis, with terms of the agreement confidential. Lawsuits the estate has filed against Ultragenyx and Viatris
read moreThe new plants are the latest in a string of recent investments AbbVie has made in U.S. manufacturing, filling out the company’s plan to infuse $100 billion into its American operations over the next decade. More: AbbVie advances US expansion
read moreRoche’s Enspryng is making solid progress as a treatment for neuromyelitis optica spectrum disorder. But the company’s efforts to expand its use to a new indication is coming up short. More: Roche halts development of Enspryng in Duchenne muscular dystrophy
read moreWith the Supreme Court’s rebuke of President Donald Trump’s emergency tariffs Friday, the U.S. administration’s international trade agenda is facing a new threat. At least one major partner has pumped the brakes on a deal that the president’s import taxes
read more
QUASAR long‑term extension results highlight durable clinical and endoscopic outcomes More: Tremfya data show sustained remission in ulcerative colitis through 3 years Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals